Korea’s Dong-A Wins Court Battle Over Rebate-Related Price Cuts
This article was originally published in PharmAsia News
Executive Summary
The domestic pharma, in which GSK holds a minority stake, won a key battle with the government while its Korean peer Chong Kun Dang lost a similar case and saw 16 drugs take a price cut.
You may also be interested in...
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.